Free Trial
NASDAQ:CGTX

Cognition Therapeutics (CGTX) Stock Price, News & Analysis

Cognition Therapeutics logo
$2.51 -0.55 (-17.97%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Cognition Therapeutics Stock (NASDAQ:CGTX)

Key Stats

Today's Range
$2.46
$2.79
50-Day Range
$0.26
$3.18
52-Week Range
$0.22
$3.83
Volume
11.91 million shs
Average Volume
4.94 million shs
Market Capitalization
$184.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.83
Consensus Rating
Buy

Company Overview

Cognition Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

CGTX MarketRank™: 

Cognition Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 787th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cognition Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cognition Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cognition Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cognition Therapeutics is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cognition Therapeutics is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cognition Therapeutics has a P/B Ratio of 24.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cognition Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.68% of the float of Cognition Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cognition Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cognition Therapeutics has recently decreased by 28.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cognition Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cognition Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.68% of the float of Cognition Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cognition Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cognition Therapeutics has recently decreased by 28.21%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cognition Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Cognition Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    42 people have searched for CGTX on MarketBeat in the last 30 days. This is an increase of 31% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.40% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cognition Therapeutics' insider trading history.
Receive CGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CGTX Stock News Headlines

Cognition Therapeutics launches $30M share offering
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
Cognition Therapeutics Regains Nasdaq Compliance
See More Headlines

CGTX Stock Analysis - Frequently Asked Questions

Cognition Therapeutics' stock was trading at $0.7013 at the beginning of 2025. Since then, CGTX shares have increased by 255.8% and is now trading at $2.4950.

Cognition Therapeutics, Inc. (NASDAQ:CGTX) issued its earnings results on Thursday, August, 7th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01.

Cognition Therapeutics (CGTX) raised $45 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share.

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Eli Lilly and Company (LLY), Meta Platforms (META), GE Aerospace (GE), Arista Networks (ANET) and Celestica (CLS).

Company Calendar

Last Earnings
8/07/2025
Today
8/28/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGTX
CIK
1455365
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$4.00
Low Price Target
$1.50
Potential Upside/Downside
-7.4%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$33.97 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-251.23%
Return on Assets
-130.75%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.54
Quick Ratio
1.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
30.60

Miscellaneous

Outstanding Shares
73,470,000
Free Float
62,892,000
Market Cap
$224.82 million
Optionable
Not Optionable
Beta
1.00

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:CGTX) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners